BenzingaAugust 14, 2026 at 8:00 AM NY2 Months Ago
TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341
TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $325 to $341.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
